Since the first patient received allogeneic hematopoietic cell transplantation (allo-HCT) to treat thalassemia, an inherited blood disorder affecting hemoglobin, in 1982, the therapy has rapidly grown in popularity. More than 8,000 transplants took place in 2021 according to the National Marrow Donor Program, and the procedure is now used to treat various blood cancers, inherited diseases, and sickle cell disease.

Artiva Biotherapeutics has upsized its IPO to $167 million as the allogeneic natural killer (NK) cell therapy prepares to list on the Nasdaq this morning.

Though his real name isn’t known, there’s no doubt that he’ll go down in history. An adult man dubbed “The Next Berlin Patient” has been declared the seventh person to be cured of HIV, and his case provides valuable information that could lead to a more broadly accessible approach for the 39 million people living with the virus around the globe.

Low double-digit growth in quarterly medical device sales has pushed Abbott to nudge up its earnings projections for the year.

After mulling over the data from a failed phase 2 trial, Johnson & Johnson has decided to halt development of its Addex Therapeutics-partnered epilepsy drug, Fierce Biotech has learned.

A $21 million public-private project led by the Foundation for the National Institutes of Health (FNIH) will see government agencies, nonprofits and industry giants hunt for biomarkers that distinguish Parkinson’s diseases from similar conditions.

Three people with autoimmune diseases have responded positively to allogeneic CAR-T therapy, marking a first for the “off-the-shelf” cell therapy tech.

After welcoming Shockwave Medical to its stable of medtech businesses earlier this year, Johnson & Johnson reported that its new acquisition had slightly bumped up its sales growth for the quarter.

Three months after The Column Group acquired NGM Bio to take the biotech private, the VC firm has overseen a $122 million fundraise to fuel clinical trials of NGM’s two lead assets.

Roche’s $2.7 billion bet on Carmot Therapeutics has delivered another early win. Participants in a phase 1 trial lost 7.3% of their body weight after taking Carmot’s oral GLP-1 prospect for four weeks, suggesting the candidate can hold its own against rival molecules from the likes of Eli Lilly and Pfizer.